1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oral Obesity Therapies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oral Obesity Therapies Market, by Drug Type
8.1.1 Appetite Suppressants
8.1.1.1. Market Revenue and Forecast
8.1.2. Lipase Inhibitors
8.1.2.1. Market Revenue and Forecast
8.1.3. Serotonin Receptor Agonists
8.1.3.1. Market Revenue and Forecast
9.1. Oral Obesity Therapies Market, by Distribution Channel
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast
9.1.2. Online Pharmacies
9.1.2.1. Market Revenue and Forecast
9.1.3. Retail Pharmacies
9.1.3.1. Market Revenue and Forecast
10.1. Oral Obesity Therapies Market, by Patient Type
10.1.1. Adults
10.1.1.1. Market Revenue and Forecast
10.1.2. Adolescents
10.1.2.1. Market Revenue and Forecast
10.1.3. Children
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type
11.1.2. Market Revenue and Forecast, by Distribution Channel
11.1.3. Market Revenue and Forecast, by Patient Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type
11.1.4.2. Market Revenue and Forecast, by Distribution Channel
11.1.4.3. Market Revenue and Forecast, by Patient Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type
11.1.5.2. Market Revenue and Forecast, by Distribution Channel
11.1.5.3. Market Revenue and Forecast, by Patient Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type
11.2.2. Market Revenue and Forecast, by Distribution Channel
11.2.3. Market Revenue and Forecast, by Patient Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type
11.2.4.2. Market Revenue and Forecast, by Distribution Channel
11.2.4.3. Market Revenue and Forecast, by Patient Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type
11.2.5.2. Market Revenue and Forecast, by Distribution Channel
11.2.5.3. Market Revenue and Forecast, by Patient Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type
11.2.6.2. Market Revenue and Forecast, by Distribution Channel
11.2.6.3. Market Revenue and Forecast, by Patient Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type
11.2.7.2. Market Revenue and Forecast, by Distribution Channel
11.2.7.3. Market Revenue and Forecast, by Patient Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type
11.3.2. Market Revenue and Forecast, by Distribution Channel
11.3.3. Market Revenue and Forecast, by Patient Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type
11.3.4.2. Market Revenue and Forecast, by Distribution Channel
11.3.4.3. Market Revenue and Forecast, by Patient Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type
11.3.5.2. Market Revenue and Forecast, by Distribution Channel
11.3.5.3. Market Revenue and Forecast, by Patient Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type
11.3.6.2. Market Revenue and Forecast, by Distribution Channel
11.3.6.3. Market Revenue and Forecast, by Patient Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type
11.3.7.2. Market Revenue and Forecast, by Distribution Channel
11.3.7.3. Market Revenue and Forecast, by Patient Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type
11.4.2. Market Revenue and Forecast, by Distribution Channel
11.4.3. Market Revenue and Forecast, by Patient Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type
11.4.4.2. Market Revenue and Forecast, by Distribution Channel
11.4.4.3. Market Revenue and Forecast, by Patient Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type
11.4.5.2. Market Revenue and Forecast, by Distribution Channel
11.4.5.3. Market Revenue and Forecast, by Patient Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type
11.4.6.2. Market Revenue and Forecast, by Distribution Channel
11.4.6.3. Market Revenue and Forecast, by Patient Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type
11.4.7.2. Market Revenue and Forecast, by Distribution Channel
11.4.7.3. Market Revenue and Forecast, by Patient Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type
11.5.2. Market Revenue and Forecast, by Distribution Channel
11.5.3. Market Revenue and Forecast, by Patient Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type
11.5.4.2. Market Revenue and Forecast, by Distribution Channel
11.5.4.3. Market Revenue and Forecast, by Patient Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type
11.5.5.2. Market Revenue and Forecast, by Distribution Channel
11.5.5.3. Market Revenue and Forecast, by Patient Type
12.1. Currax Pharmaceuticals, LLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Vivus, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. NutriSystem, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Medtronic
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Ethicon, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sun Pharmaceutical Industries Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Kellogg Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Novo Nordisk A/S
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
